Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression. - Derer S; Berger S; Schlaeth M; Schneider-Merck T; Klausz K; Lohse S; Overdijk MB; Dechant M; Kellner C; Nagelmeier I; Scheel AH; Lammerts van Bueren JJ; et al. (Neoplasia (New York, N.Y.), 2012)